#1 Clinical Trials Search in Europe

Fingolimod Hydrochloride

Fingolimod Hydrochloride, also known as Gilenya, is a medication that has been the subject of several clinical trials exploring its potential in treating various conditions. Originally developed for multiple sclerosis, researchers are now investigating its efficacy in addressing other neurological issues, including chemotherapy-induced neuropathy and stroke. This article delves into the ongoing studies and their implications for patients.

Table of Contents

What is Fingolimod Hydrochloride?

Fingolimod hydrochloride, also known by the brand name Gilenya, is a medication primarily used to treat multiple sclerosis (MS). It is also known by other names such as FTY720 and FTY-720[1][2]. Fingolimod is an oral medication that works by modulating the immune system to reduce inflammation and nerve damage in MS patients.

Uses of Fingolimod

Fingolimod is primarily used to treat relapsing forms of multiple sclerosis (MS). MS is a condition where the immune system mistakenly attacks the protective covering of nerves in the brain and spinal cord, leading to various neurological symptoms[3]. However, research is ongoing to explore its potential in treating other conditions:

  • Acute Ischemic Stroke: Studies are investigating whether fingolimod can help reduce brain inflammation and improve outcomes when combined with other treatments for stroke[4].
  • Chemotherapy-Induced Neuropathy: Researchers are exploring if fingolimod can prevent or treat nerve pain caused by certain cancer treatments[1][5].
  • Rett Syndrome: A rare genetic disorder affecting brain development in girls. A small study is looking at whether fingolimod might help slow down the progression of symptoms[2].

How Fingolimod Works

Fingolimod works by modulating the immune system in several ways:

  • It acts on specific receptors called sphingosine-1-phosphate (S1P) receptors, which are found on immune cells[4].
  • This action prevents certain immune cells (lymphocytes) from leaving the lymph nodes and entering the bloodstream[6].
  • By reducing the number of these immune cells circulating in the body, it helps decrease inflammation and damage to the nervous system in MS patients.
  • In other conditions like stroke or chemotherapy-induced neuropathy, it may help by reducing inflammation or protecting nerve cells[4][1].

How Fingolimod is Administered

Fingolimod is typically taken as an oral capsule once daily. The usual dose for adults with MS is 0.5 mg per day[6]. However, the dosage may vary depending on the condition being treated and the specific study protocol. For example:

  • In MS studies, patients usually take 0.5 mg once daily[3].
  • In studies for chemotherapy-induced neuropathy, patients may take the medication on specific days related to their chemotherapy schedule[1].
  • For other conditions like stroke, the dosing schedule may be different and determined by the research protocol[4].

Effectiveness of Fingolimod

Fingolimod has shown effectiveness in treating relapsing forms of multiple sclerosis. Studies have demonstrated that it can:

  • Reduce the frequency of MS relapses (flare-ups of symptoms)[6].
  • Slow down the progression of disability in MS patients[6].
  • Reduce the number of new or enlarging brain lesions seen on MRI scans[6].
  • Potentially slow down brain volume loss (atrophy) associated with MS[6].

Its effectiveness in other conditions is still being researched and is not yet fully established.

Potential Side Effects

Like all medications, fingolimod can cause side effects. Some potential side effects observed in clinical trials include:

  • Slowed heart rate: Especially after the first dose, which is why patients are usually monitored closely when starting the medication[3].
  • Increased risk of infections: Due to its effects on the immune system[6].
  • Liver function changes: Regular blood tests may be needed to monitor liver health[3].
  • Macular edema: A type of swelling in the eye that can affect vision[3].
  • Lymphopenia: A decrease in certain types of white blood cells[3].

It’s important to discuss potential side effects with your healthcare provider, as they can help monitor and manage these issues.

Ongoing Research

Researchers continue to study fingolimod to better understand its effects and explore its potential in treating other conditions. Some areas of ongoing research include:

  • Long-term safety and effectiveness in MS patients[6].
  • Its potential use in acute ischemic stroke[4].
  • Prevention and treatment of chemotherapy-induced neuropathy[1][5].
  • Possible benefits in rare conditions like Rett Syndrome[2].
  • Effects on specific immune system components (cytokines and chemokines) in MS patients[7].
  • Safety during pregnancy in women with MS[8].

These ongoing studies help researchers and healthcare providers better understand how to use fingolimod effectively and safely in various conditions.

Aspect Details
Primary Uses Treatment of relapsing-remitting multiple sclerosis (RRMS)
Emerging Applications Prevention and treatment of chemotherapy-induced neuropathy, potential benefits in acute ischemic stroke
Administration Oral capsule, typically 0.5 mg once daily
Key Monitored Effects Changes in neurological symptoms, lymphocyte counts, heart rate, liver function, macular edema
Trial Durations Vary from a few months to over a year, depending on study objectives
Mechanism of Action Modulates sphingosine-1-phosphate receptors, reducing lymphocyte migration to central nervous system
Population Studied Adults with RRMS, cancer patients with chemotherapy-induced neuropathy, acute ischemic stroke patients

FAQ

  • What is Fingolimod Hydrochloride primarily used for? Fingolimod Hydrochloride is primarily used to treat relapsing-remitting multiple sclerosis (RRMS). It works by reducing the number of white blood cells (lymphocytes) that can reach the brain and spinal cord, which may help decrease the damage caused by MS.
  • Are there any new potential uses for Fingolimod being studied? Yes, researchers are exploring Fingolimod's potential in treating other conditions. Current studies are looking at its effectiveness in preventing and treating chemotherapy-induced neuropathy, as well as its possible benefits in acute ischemic stroke patients.
  • How is Fingolimod typically administered? Fingolimod is usually taken orally as a capsule, typically once daily. The standard dose is 0.5 mg, but some trials are exploring different dosing regimens depending on the condition being treated.
  • What are some of the side effects being monitored in Fingolimod trials? Researchers are closely monitoring various side effects, including bradycardia (slow heart rate), liver function abnormalities, macular edema (swelling in the eye), and changes in blood lymphocyte counts. They're also tracking any improvements in neurological symptoms related to the conditions being studied.
  • How long do typical clinical trials for Fingolimod last? The duration of Fingolimod trials varies depending on the study's objectives. Some trials last for a few months, while others can extend up to a year or more. For example, one study on multiple sclerosis is following patients for 12 months, while a trial on chemotherapy-induced neuropathy lasts for 4 weeks with a 3-month follow-up period.

Ongoing Clinical Trials on Fingolimod Hydrochloride

  • Study on the Effectiveness and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Children with Multiple Sclerosis

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Croatia Estonia France Germany +7

Glossary

  • Fingolimod Hydrochloride: A medication used to treat multiple sclerosis that works by trapping certain white blood cells in the lymph nodes, preventing them from contributing to autoimmune reactions.
  • Relapsing-Remitting Multiple Sclerosis (RRMS): A form of multiple sclerosis characterized by clearly defined attacks of new or increasing neurologic symptoms, followed by periods of partial or complete recovery.
  • Chemotherapy-Induced Peripheral Neuropathy (CIPN): Nerve damage caused by cancer treatments, resulting in symptoms like numbness, tingling, and pain in the hands and feet.
  • Acute Ischemic Stroke: A sudden interruption in the blood supply to the brain, typically caused by a blood clot, leading to a lack of oxygen and potential brain damage.
  • Macular Edema: Swelling or thickening of the macula, the part of the eye responsible for detailed central vision, which can occur as a side effect of some medications.
  • Bradycardia: Abnormally slow heart rate, typically defined as a heart rate of less than 60 beats per minute in adults.
  • Lymphocyte: A type of white blood cell that is part of the immune system and helps protect the body from infections and diseases.
  • Sphingosine-1-phosphate receptor: A protein found on the surface of certain cells that Fingolimod interacts with to produce its therapeutic effects.
  • Neuropathy: A general term for diseases or malfunctions of the nerves, which can result in numbness, tingling, muscle weakness, and pain in various parts of the body.
  • Thrombectomy: A surgical procedure to remove a blood clot from a blood vessel, often used in the treatment of acute ischemic stroke.

References

  1. https://clinicaltrials.gov/study/NCT03941743
  2. https://clinicaltrials.gov/study/NCT02061137
  3. https://clinicaltrials.gov/study/NCT04480853
  4. https://clinicaltrials.gov/study/NCT02956200
  5. https://clinicaltrials.gov/study/NCT03943498
  6. https://clinicaltrials.gov/study/NCT01201356
  7. https://clinicaltrials.gov/study/NCT02373098
  8. https://clinicaltrials.gov/study/NCT01285479